[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Table 1.  Clinical Characteristics and Outcomes of Patients With Cancer With SARS-CoV-2 Infection
Clinical Characteristics and Outcomes of Patients With Cancer With SARS-CoV-2 Infection
Table 2.  COVID-19 Pneumonia in Patients With NSCLC of Different Age Groups Treated at the Zhongnan Hospital of Wuhan University
COVID-19 Pneumonia in Patients With NSCLC of Different Age Groups Treated at the Zhongnan Hospital of Wuhan University
1.
Chen  N, Zhou  M, Dong  X,  et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.  Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7PubMedGoogle ScholarCrossref
2.
Wu  YC, Chen  CS, Chan  YJ.  The outbreak of COVID-19: an overview.  J Chin Med Assoc. 2020;83(3):217-220. doi:10.1097/JCMA.0000000000000270PubMedGoogle ScholarCrossref
3.
Wang  D, Hu  B, Hu  C,  et al.  Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.  JAMA. Published online February 7, 2020. doi:10.1001/jama.2020.1585PubMedGoogle Scholar
4.
Kamboj  M, Sepkowitz  KA.  Nosocomial infections in patients with cancer.  Lancet Oncol. 2009;10(6):589-597. doi:10.1016/S1470-2045(09)70069-5PubMedGoogle ScholarCrossref
5.
Guan  WJ, Ni  ZY, Hu  Y,  et al; China Medical Treatment Expert Group for Covid-19.  Clinical characteristics of coronavirus disease 2019 in China.  N Engl J Med.Published online February 28, 2020. doi:10.1056/NEJMoa2002032PubMedGoogle Scholar
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    1 Comment for this article
    Estimated Infection rate among Italian Cancer Patients
    Raffaele Giusti, MD | Medical Oncology Unit, Sant'Andrea Hospital of Rome
    Dear Author,
    The reported data are very interesting and underline a particular problem that we are observing among Italian cancer patients population.
    At today, We do not have retrospective analysis, but, according to the reported data from ISS (Istituto Superiore di Sanità, https://www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_20_marzo_eng.pdf, accessed on march 25) in the 19.5% the Most common comorbidities observed in COVID-19 positive deceased patients were cancer.
    So my question is that maybe we're doing something wrong?
    Thank you.
    RG
    CONFLICT OF INTEREST: None Reported
    Views 8,978
    Citations 0
    Research Letter
    March 25, 2020

    SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China

    Author Affiliations
    • 1Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
    • 2Hubei Key Laboratory of Tumor Biological Behaviors, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
    • 3Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, People’s Republic of China
    • 4Division of Radiation Oncology, Division of Medical Sciences, National Cancer Centre Singapore, Singapore
    • 5Oncology Academic Programme, Duke-NUS Medical School, Singapore
    JAMA Oncol. Published online March 25, 2020. doi:10.1001/jamaoncol.2020.0980

    In December 2019, an outbreak of 2019 novel coronavirus disease (COVID-19) occurred in Wuhan, Hubei, which has been linked to the severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2). It is characterized by rapid human-to-human transmission from droplet contamination.1,2 A report of 138 hospitalized patients from a single institution (Zhongnan Hospital of Wuhan University) indicated that hospital-acquired transmission accounted for 41.3% of these admitted patients, thus implicating the hospital environment as a source of spread of the virus.3 Patients with cancer are often recalled to the hospital for treatment and monitoring, and hence, they may be at risk of contracting COVID-19. Moreover, cancer treatments such as chemotherapy and radiotherapy are immunosuppressive. Here, we report the incidence and outcomes of SARS-CoV-2 infection in cancer patients who were treated at a tertiary cancer institution in Wuhan.

    Methods

    We reviewed the medical records, including demographic, clinical, and treatment data of 1524 patients with cancer who were admitted to the Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, from December 30, 2019, to February 17, 2020 (data cutoff date). COVID-19 pneumonia was diagnosed based on the updated COVID-19 Diagnostic Criteria, 5th Edition (Supplement). Outcomes of COVID-19 among patients with cancer were reported.

    This retrospective study was approved by the Zhongnan Hospital of Wuhan University ethics committee (2020039). Waiver of informed consent was approved for the aggregated data; verbal informed consent was obtained from the living patients with COVID-19.

    Results

    We estimated the infection rate of SARS-CoV-2 in patients with cancer from our single institution at 0.79% (12 of 1524 patients; 95% CI, 0.3%-1.2%). This was higher than the cumulative incidence of all diagnosed COVID-19 cases that was reported in the city of Wuhan over the same time period (0.37%; 41 152 of 11 081 000 cases; data cutoff on February 17, 2020). Clinical details on the cancer diagnoses and treatment history are summarized in Table 1. The median age of infected patients was 66 years (range, 48 to 78 years); 8 of 12 patients (66.7%) were older than 60 years. Seven of 12 (58.3%) patients had non–small cell lung carcinoma (NSCLC). Five (41.7%) were being treated with either chemotherapy with or without immunotherapy (n = 3) or radiotherapy (n = 2). Three patients (25.0%) developed SARS; 1 patient required intensive-level care. As of March 10, 2020, 6 patients (50.0%) had been discharged, whereas 3 deaths (25.0%) were recorded.

    We also interrogated the association of SARS-Cov-2 infection with age and concurrent NSCLC diagnosis. Of the 1524 patients with cancer who were screened, 228 had NSCLC. We found that patients with NSCLC older than 60 years had a higher incidence of COVID-19 than those aged 60 years or younger (4.3% vs 1.8%) (Table 2).

    Discussion

    It is hypothesized that patients with cancer may be susceptible to an infection during a viral epidemic owing to their immunocompromised status.4 This study highlights the following observations: patients with cancer from the epicenter of a viral epidemic harbored a higher risk of SARS-CoV-2 infection (OR, 2.31; 95% CI, 1.89-3.02) compared with the community. However, fewer than half of these infected patients were undergoing active treatment for their cancers. Next, we observed that older patients (>60 years) and patients with NSCLC may be at risk of COVID-19. Nonetheless, a population study of 1099 patients with COVID-19 did not indicate that age was associated with susceptibility to infection.5 A larger sample size in patients with cancer will resolve these potential associations. Finally, our findings imply that hospital admission and recurrent hospital visits are potential risk factors for SARS-CoV-2 infection.

    We propose that aggressive measures be undertaken to reduce frequency of hospital visits of patients with cancer during a viral epidemic going forward. For patients who require treatment, proper isolation protocols must be in place to mitigate the risk of SARS-CoV-2 infection.

    Back to top
    Article Information

    Corresponding Authors: Conghua Xie, MD, Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan 430071, People’s Republic of China (chxie_65@whu.edu.cn); Melvin L. K. Chua, MBBS, PhD, Division of Radiation Oncology, National Cancer Centre Singapore, 11 Hospital Crescent, Singapore 169610 (melvin.chua.l.k@singhealth.com.sg).

    Accepted for Publication: March 11, 2020.

    Published Online: March 25, 2020. doi:10.1001/jamaoncol.2020.0980

    Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2020 Yu J et al. JAMA Oncology.

    Author Contributions: Drs Xie and Chua had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Yu and Ouyang contributed equally as co–first authors. Drs Chua and Xie contributed equally as co–senior authors.

    Study concept and design: All authors.

    Acquisition, analysis, or interpretation of data: All authors.

    Drafting of the manuscript: Yu, Chua.

    Critical revision of the manuscript for important intellectual content: Yu, Ouyang, Xie.

    Statistical analysis: Yu, Chua.

    Administrative, technical, or material support: All authors.

    Study supervision: Yu, Chua, Xie.

    Funding/Support: Dr Chua is supported by the National Medical Research Council Clinician-Scientist Award (CSA/0027/2018).

    Role of the Funder/Sponsor: The National Medical Research Council had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

    Conflict of Interest Disclosures: No conflicts are reported.

    Additional Contributions: We thank all the patients who consented to this study, and the frontline healthcare professionals who are involved in patient care during this pandemic.

    References
    1.
    Chen  N, Zhou  M, Dong  X,  et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.  Lancet. 2020;395(10223):507-513. doi:10.1016/S0140-6736(20)30211-7PubMedGoogle ScholarCrossref
    2.
    Wu  YC, Chen  CS, Chan  YJ.  The outbreak of COVID-19: an overview.  J Chin Med Assoc. 2020;83(3):217-220. doi:10.1097/JCMA.0000000000000270PubMedGoogle ScholarCrossref
    3.
    Wang  D, Hu  B, Hu  C,  et al.  Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China.  JAMA. Published online February 7, 2020. doi:10.1001/jama.2020.1585PubMedGoogle Scholar
    4.
    Kamboj  M, Sepkowitz  KA.  Nosocomial infections in patients with cancer.  Lancet Oncol. 2009;10(6):589-597. doi:10.1016/S1470-2045(09)70069-5PubMedGoogle ScholarCrossref
    5.
    Guan  WJ, Ni  ZY, Hu  Y,  et al; China Medical Treatment Expert Group for Covid-19.  Clinical characteristics of coronavirus disease 2019 in China.  N Engl J Med.Published online February 28, 2020. doi:10.1056/NEJMoa2002032PubMedGoogle Scholar
    ×